AR074465A2 - Uso de derivados de acidos grasos para tratamiento de desordenes de secrecion externa - Google Patents
Uso de derivados de acidos grasos para tratamiento de desordenes de secrecion externaInfo
- Publication number
- AR074465A2 AR074465A2 ARP090104665A ARP090104665A AR074465A2 AR 074465 A2 AR074465 A2 AR 074465A2 AR P090104665 A ARP090104665 A AR P090104665A AR P090104665 A ARP090104665 A AR P090104665A AR 074465 A2 AR074465 A2 AR 074465A2
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- hydroxyl
- lower alkyl
- csc
- oxo
- Prior art date
Links
- 230000028327 secretion Effects 0.000 title abstract 3
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 208000005946 Xerostomia Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de un compuesto derivado de ácido graso que está representado por la fórmula general (1) en donde L y M son hidrógeno, hidroxilo, halógeno, alquilo inferior, hidroxialquilo (inferior) u oxo, en donde por lo menos uno de L y M es un grupo distinto do hidrógeno, y el anillo de cinco miembros puede tener al menos un enlace doble; A es -CH2OH, -COCH2OH, -COOH o su derivado funcional; B es un enlace simple, -CH2-CH2-, -CH=CH-, -CsC-, -CH2-CH2-CH2-, -CH=CH-CH2-, -CH2-CH=CH-, -CsC-CH2-, o -CH2-CsC-; Z se selecciona del grupo de fórmulas (2), en donde R4 y R5 son H, hidroxilo, halógeno, alquilo inferior, alcoxilo inferior o hidroxialquilo (inferior), en donde R4 y R5 no son hidroxilo y alcoxilo inferior al mismo tiempo; X1 y X2 son hidrógeno, alquilo inferior o halógeno; R1 es un residuo de hidrocarburo alifático medio-inferior no saturado o suturado divalente que es sustituido o no sustituido por halógeno, oxo, hidroxilo alquilo inferior, arilo o heterocíclico; R2 es un enlace simple o alquileno inferior; y R3 es alquilo inferior, alcoxilo inferior, cicloalquilo (inferior), cicloalquiloxilo (inferior), arilo, ariloxilo, heterocíclico o heterocíclico-oxilo, con la provisión que Z es oxo y/o al menos uno de X1 y X2 es halógeno, excluyendo el compuesto 11-deshidroxi-13,14-dihidro-15-ceto-16,16-difluoro PGE1, sus sales, éteres, ésteres y amidas del mismo, el cual es para preparar una composición farmacéutica para inducir la secreción externa en un paciente con desórdenes de la secreción externa. Reivindicación 2: El uso de acuerdo con la reivindicación 1, caracterizado porque dicho desorden externo es el síndrome de ojo seco. Reivindicación 5: El uso de acuerdo con la reivindicación 1, caracterizado porque dicho desorden externo es hiposalivación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14362799P | 1999-07-14 | 1999-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074465A2 true AR074465A2 (es) | 2011-01-19 |
Family
ID=22504885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103635A AR029381A1 (es) | 1999-07-14 | 2000-07-14 | Composicion para tratamiento de los desordenes de secrecion externa, metodo que la emplea y uso de un derivado de acido graso para prepararla |
| ARP090104665A AR074465A2 (es) | 1999-07-14 | 2009-12-03 | Uso de derivados de acidos grasos para tratamiento de desordenes de secrecion externa |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103635A AR029381A1 (es) | 1999-07-14 | 2000-07-14 | Composicion para tratamiento de los desordenes de secrecion externa, metodo que la emplea y uso de un derivado de acido graso para prepararla |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6566398B1 (es) |
| EP (1) | EP1223925B1 (es) |
| JP (2) | JP4167828B2 (es) |
| KR (1) | KR100750553B1 (es) |
| CN (4) | CN100548977C (es) |
| AR (2) | AR029381A1 (es) |
| AT (1) | ATE344027T1 (es) |
| AU (1) | AU779936B2 (es) |
| BR (1) | BRPI0012387B1 (es) |
| CA (1) | CA2377661C (es) |
| CZ (1) | CZ303958B6 (es) |
| DE (1) | DE60031710T2 (es) |
| DK (1) | DK1223925T3 (es) |
| ES (1) | ES2273706T3 (es) |
| HK (1) | HK1048443B (es) |
| HU (1) | HU229318B1 (es) |
| IL (2) | IL147440A0 (es) |
| MX (1) | MXPA02000437A (es) |
| NO (1) | NO323908B1 (es) |
| PT (1) | PT1223925E (es) |
| RU (1) | RU2264816C2 (es) |
| TR (1) | TR200200065T2 (es) |
| TW (1) | TWI225398B (es) |
| WO (1) | WO2001005388A2 (es) |
| ZA (1) | ZA200109726B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732487B2 (en) * | 2001-11-19 | 2010-06-08 | Sucampo Ag | Method for treating a disease or condition responsive to opening of C1C-2 channel |
| AU2003235452A1 (en) * | 2002-06-14 | 2003-12-31 | Alcon, Inc. | Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth |
| US20040076695A1 (en) * | 2002-07-08 | 2004-04-22 | Advanced Vision Research | EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| US20040185075A1 (en) | 2003-01-31 | 2004-09-23 | Maria Dalko | Use of at least one (dihydro)jasmonic acid derivative for treating dry skin |
| FR2850571B1 (fr) * | 2003-01-31 | 2006-07-07 | Oreal | Utilisation d'un derive d'acide(dihydro) jasmonique pour le traitement des peaux seches |
| US9216106B2 (en) * | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
| US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| WO2005032534A1 (ja) | 2003-10-06 | 2005-04-14 | Ophtecs Corporation | 涙液異常の治療のための眼科用組成物 |
| US7923471B2 (en) | 2004-05-14 | 2011-04-12 | Alcon, Inc. | Method of treating dry eye disorders and uveitis |
| US20070265341A1 (en) * | 2004-07-01 | 2007-11-15 | The Schepens Eye Research Institute Inc. | Compositions and methods for treating eye disorders and conditions |
| CN101043884A (zh) * | 2004-07-01 | 2007-09-26 | 谢彭斯眼科研究公司 | 用于治疗眼部疾病和病症的组合物和方法 |
| AU2006209072B2 (en) * | 2005-01-27 | 2011-02-24 | Sucampo Ag | Method and composition for treating central nervous system disorders |
| US8143316B2 (en) * | 2005-03-04 | 2012-03-27 | Sucampo Ag | Method for treating peripheral vascular diseases |
| US7638142B2 (en) * | 2005-10-12 | 2009-12-29 | Vitamin Science, Inc. | Therapeutic composition for the treatment of dry eye syndrome |
| CA2637275C (en) | 2006-01-24 | 2014-12-09 | R-Tech Ueno, Ltd. | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
| JP2010519177A (ja) * | 2007-02-27 | 2010-06-03 | スキャンポ・アーゲー | ミトコンドリアを保護するための組成物および方法 |
| US20090053309A1 (en) * | 2007-08-24 | 2009-02-26 | Axiomedic Ltd., Gibraltar | Adhesive compositions for the treatment of xerostomia |
| US9161909B2 (en) | 2007-08-24 | 2015-10-20 | Axiomedic Ltd. | Adhesive compositions for the treatment of xerostomia |
| US20090082442A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched lubiprostone |
| US9884082B2 (en) | 2008-11-13 | 2018-02-06 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
| US9597278B2 (en) | 2008-11-13 | 2017-03-21 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
| EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| CA2817589A1 (en) | 2010-11-16 | 2012-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treatment of dry eye |
| US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
| US20210121430A1 (en) | 2011-07-18 | 2021-04-29 | Prn Physician Recommended Nutriceuticals, Llc | Omega-3 fatty acid supplementation for use in treating dry eye |
| US9115078B2 (en) | 2011-07-18 | 2015-08-25 | Physicians Recommended Nutriceuticals, Llc | Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands |
| US9381183B2 (en) | 2012-07-18 | 2016-07-05 | Physicians Recommended Nutriceuticals, Llc | Methods for improving the quality of the meibum composition of meibomian glands |
| US10709680B2 (en) | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| AU2012293157A1 (en) * | 2011-08-05 | 2014-03-13 | Sucampo Ag | Method for treating schizophrenia |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| EP2986339A4 (en) | 2013-04-19 | 2016-12-21 | Oculeve Inc | Nasal stimulation devices and methods |
| JP6735742B2 (ja) | 2014-10-22 | 2020-08-05 | オキュリーブ， インコーポレイテッド | ドライアイの治療のための刺激装置及び方法 |
| US10918864B2 (en) | 2016-05-02 | 2021-02-16 | Oculeve, Inc. | Intranasal stimulation for treatment of meibomian gland disease and blepharitis |
| WO2019208435A1 (ja) | 2018-04-26 | 2019-10-31 | ライオン株式会社 | 外分泌促進剤 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4131651A (en) * | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
| US4409205A (en) * | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| IE49783B1 (en) * | 1979-05-18 | 1985-12-11 | Efamol Ltd | Pharmaceutical and dietary composition comprising epsilon-linolenic acids |
| GB8319073D0 (en) * | 1983-07-14 | 1983-08-17 | Efamol Ltd | Fatty acid compositions |
| JPH07103096B2 (ja) * | 1987-01-28 | 1995-11-08 | 株式会社上野製薬応用研究所 | プロスタグランジンｄ類およびそれを含む鎮静・睡眠剤 |
| JPH0688966B2 (ja) * | 1987-01-28 | 1994-11-09 | 株式会社アールテック・ウエノ | プロスタグランジンｅ類およびそれを含む抗潰瘍剤 |
| DE3711164A1 (de) | 1987-04-02 | 1988-10-20 | Zeiss Carl Fa | Steckelementeinrichtung zur halterung von bauteilen in stapeln |
| CA1324129C (en) * | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
| JPS63277604A (ja) * | 1987-05-11 | 1988-11-15 | Showa Denko Kk | α−リノレン酸含有化粧料 |
| JPH0692305B2 (ja) * | 1987-05-15 | 1994-11-16 | 株式会社上野製薬応用研究所 | 体温上昇剤 |
| ATE108330T1 (de) * | 1987-09-18 | 1994-07-15 | R Tech Ueno Ltd | Hypotensive okulare mittel. |
| SU1673123A1 (ru) * | 1987-12-04 | 1991-08-30 | Научно-исследовательский институт морфологии человека АМН СССР | Способ лечени болезни и синдрома Шегрена |
| JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体 |
| AU4216089A (en) | 1988-08-12 | 1990-03-05 | Joel E. Bernstein | Method and composition for treating and preventing dry skin disorders |
| CA2027814C (en) * | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
| JPH07100655B2 (ja) * | 1990-04-04 | 1995-11-01 | 株式会社アールテック・ウエノ | 白内障処置剤 |
| TW224942B (es) * | 1990-04-04 | 1994-06-11 | Adka Ueno Kk | |
| EP0455448B1 (en) * | 1990-05-01 | 1998-12-09 | R-Tech Ueno Ltd. | Treatment of pancreatic disease with 15-keto-prostaglandin E compounds |
| JPH07113012B2 (ja) * | 1991-01-29 | 1995-12-06 | 株式会社アールテック・ウエノ | 新規１５−ケト−プロスタグランジン類 |
| ES2093774T3 (es) * | 1991-03-14 | 1997-01-01 | R Tech Ueno Ltd | Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina. |
| US5369127A (en) * | 1993-04-21 | 1994-11-29 | Allergan, Inc. | 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
| TW420611B (en) * | 1995-03-10 | 2001-02-01 | R Tech Ueno Ltd | Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder |
| US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| AU2183900A (en) * | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| AU2183800A (en) * | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Prostaglandin e agonists for treatment of dry eye |
| AU2006209072B2 (en) * | 2005-01-27 | 2011-02-24 | Sucampo Ag | Method and composition for treating central nervous system disorders |
| US8143316B2 (en) * | 2005-03-04 | 2012-03-27 | Sucampo Ag | Method for treating peripheral vascular diseases |
-
2000
- 2000-07-12 TW TW089113876A patent/TWI225398B/zh not_active IP Right Cessation
- 2000-07-13 MX MXPA02000437A patent/MXPA02000437A/es active IP Right Grant
- 2000-07-13 CN CNB2006101215152A patent/CN100548977C/zh not_active Expired - Fee Related
- 2000-07-13 AU AU58533/00A patent/AU779936B2/en not_active Ceased
- 2000-07-13 ES ES00944426T patent/ES2273706T3/es not_active Expired - Lifetime
- 2000-07-13 CN CN2010101574518A patent/CN101829120B/zh not_active Expired - Fee Related
- 2000-07-13 CN CN200910205219A patent/CN101695495A/zh active Pending
- 2000-07-13 CA CA2377661A patent/CA2377661C/en not_active Expired - Lifetime
- 2000-07-13 RU RU2002103597/15A patent/RU2264816C2/ru not_active IP Right Cessation
- 2000-07-13 CN CN00810238A patent/CN1399548A/zh active Pending
- 2000-07-13 DE DE60031710T patent/DE60031710T2/de not_active Expired - Lifetime
- 2000-07-13 CZ CZ20020133A patent/CZ303958B6/cs not_active IP Right Cessation
- 2000-07-13 IL IL14744000A patent/IL147440A0/xx unknown
- 2000-07-13 JP JP2001510445A patent/JP4167828B2/ja not_active Expired - Fee Related
- 2000-07-13 TR TR2002/00065T patent/TR200200065T2/xx unknown
- 2000-07-13 HK HK03100518.0A patent/HK1048443B/en not_active IP Right Cessation
- 2000-07-13 US US09/615,703 patent/US6566398B1/en not_active Expired - Lifetime
- 2000-07-13 HU HU0202400A patent/HU229318B1/hu not_active IP Right Cessation
- 2000-07-13 DK DK00944426T patent/DK1223925T3/da active
- 2000-07-13 AT AT00944426T patent/ATE344027T1/de active
- 2000-07-13 EP EP00944426A patent/EP1223925B1/en not_active Expired - Lifetime
- 2000-07-13 PT PT00944426T patent/PT1223925E/pt unknown
- 2000-07-13 BR BRPI0012387A patent/BRPI0012387B1/pt not_active IP Right Cessation
- 2000-07-13 KR KR1020027000471A patent/KR100750553B1/ko not_active Expired - Fee Related
- 2000-07-13 WO PCT/JP2000/004696 patent/WO2001005388A2/en not_active Ceased
- 2000-07-14 AR ARP000103635A patent/AR029381A1/es not_active Application Discontinuation
-
2001
- 2001-11-27 ZA ZA200109726A patent/ZA200109726B/en unknown
-
2002
- 2002-01-02 IL IL147440A patent/IL147440A/en active IP Right Grant
- 2002-01-11 NO NO20020133A patent/NO323908B1/no not_active IP Right Cessation
-
2003
- 2003-03-04 US US10/377,743 patent/US20030171438A1/en not_active Abandoned
-
2004
- 2004-11-23 US US10/994,364 patent/US7396946B2/en not_active Expired - Fee Related
-
2008
- 2008-06-24 JP JP2008164252A patent/JP5052423B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-03 AR ARP090104665A patent/AR074465A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029381A1 (es) | Composicion para tratamiento de los desordenes de secrecion externa, metodo que la emplea y uso de un derivado de acido graso para prepararla | |
| AR056320A1 (es) | Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos | |
| AR002241A1 (es) | Derivado de 2,4-oxazolidinadiona, composicion farmaceutica que lo comprende y metodo de preparacion del mismo. | |
| CO5160347A1 (es) | Derivados de acido carbamico | |
| AR011913A1 (es) | Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos. | |
| AR110149A2 (es) | Composición catártica | |
| AR062785A1 (es) | Compuestos de 4-metilpiridopirimidinona, composiciones farmaceuticas que los contienen y usos en estados patologicos asociados al crecimiento anormal celular,tal como cancer. | |
| PE20210398A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados | |
| AR073158A1 (es) | Metodo y composicion para modular el crecimiento de celulas madre | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR051091A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR047706A1 (es) | Inhibidores de polimerasa viral | |
| AR118084A1 (es) | Inhibidores de enzimas | |
| AR076098A1 (es) | Derivados de benzofurano | |
| AR049398A1 (es) | Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados. | |
| AR056980A1 (es) | Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos | |
| ES2087097T3 (es) | Derivados de acidos fenilcarboxilicos que contienen un heterociclo. | |
| AR035237A1 (es) | Uso de un compuesto 15-cet-prostaglandina para fabricar una composicion para tratar estrenimiento inducido por drogas | |
| AR081064A1 (es) | Compuestos de tetraciclina policiclica | |
| AR063275A1 (es) | Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2. | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| MX384744B (es) | Derivado de morfinano. | |
| AR118083A1 (es) | Inhibidores de enzimas | |
| CO5580782A2 (es) | Antibioticos de glicopeptido-cefalosporina entrecruzados | |
| ES2485867T3 (es) | Compuestos opioides de carboxamido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |